🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📊 Critical discussions at #BladderCancerAcademy today! ElsieMensah gave an outstanding talk on Risk Stratification and Risk-Adjusted Management in #NMIBC. Tailoring treatment to risk level=better outcomes for our patients. Personalised care starts here!👏 #IBCG

📈 Driving improvements with @JohnMcgrath delivering a great talk on the GIRFT Guidelines Update, which helped advance #NMIBC care across the UK. Guidelines into practice = better outcomes and smarter pathways! 🛤️ #BladderCancerAcademy #NHSGIRFT #UrologyEducation

🚨Take a look at the first results of TAR-200 in papillary-only BCG unresponsive NMIBC!!! 🇺🇸Presented in Plenary Session at #AUA25 📻Stay tuned for more mature data! 🦀We move forward in #NMIBC Amer. Urol. Assn. Mark Wildgust (he/him) GUARD Consortium GUO-AEU AEU J&J Medical Affairs Oncology Hospital Universitario 12 de Octubre

☄️New Simply Oncology episode out tomorrow. 🎙️AC/DC were Back in Black but Simply Oncology is Back in Bladder ⚡️with the amazing Prof Rob Jones. Part 1 of 2 on a free ranging overview of metastatic bladder cancer treatment in the UK 🚨 Beatson Cancer Charity Fight Bladder Cancer

🗣️ Another milestone in non-muscle invasive bladder cancer research 🎗️ Adding 1 year of durvalumab to the standard intravesical BCG impacts in longer Disease Free Survival, the primary endpoint of the phase 3 pivotal #POTOMAC trial. Together with sasanlimab we have a new systemic

EUO PRIORITY ARTICLE – EDITORIAL: Lights and Shadows of Bacillus Calmette-Guérin (BCG)-exposed and BCG-unresponsive Definitions: A Practical Overview by Luca Afferi et al Read the full editorial here: euoncology.europeanurology.com/article/S2588-… #EUO #UroSoMe #MedTwitter #PriorityArticle

Had so much fun (see interview bit.ly/4j2BScj ) at the inaugural GU Early Thought Leaders 2025 Conference with Zach Klaassen where we met many future #GUOncology leaders! Prostate Cancer Foundation UroToday.com with outstanding faculty Elizabeth Plimack MD Sumanta K. Pal, MD, FASCO Arjun Balar MD Alan H Bryce Trinity J. Bivalacqua

Study introducing urine urine-based diagnostic test that measures GAGs to detect ccRCC recurrence. Test shows promise in reducing unnecessary scans and health care costs. Full interview with Dr Dabestani of Lund University 👉 bit.ly/3EjGhZx Saeed Dabestani #EAU25

NeuroSAFE PROOF study shows frozen section intraoperative margin evaluation positively impacts sexual potency and continence following radical prostatectomy. Full interview with Prof Greg Shaw of UCLH 👉 bit.ly/3EI0LLr #EAU25

💡The best systematic reviews bring together a host of treatments in one paper for an easy reference 👏Saum Ghodoussipour et al. do that for #NMIBC strategies European Urology 🔗shorturl.at/iKtml Roger Li Sarah P. Psutka MD MS Mark Tyson Bladder Cancer Advocacy Network Gianluca Giannarini

Super excited to have Henning Plage visiting us at Cleveland Clinic Urology! Can’t wait to show off our awesome team and learn a thing or two from our European Association of Urology (EAU) friend 🇩🇪🇺🇸Chris Weight Rebecca Campbell Betty Wang

Join us for International Clinical Trials Day Hear about latest cancer research success at Bart’s - new cancer blood tests, vaccines and new treatments 📆 Thurs 22nd May 10am-2pm 📍 West Wing, St Bart’s hospital Please sign up via link below Barts Charity ECMC Network (@ecmc-uk.bsky.social)

EAU Guidelines Update: European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines by Antoine G. van der Heijden et al Read the full update here: buff.ly/DFOK4dt #UroSoMe #MedTwitter #EurUrol

FDA ODAC on #UGN102 + requirement of randomized #trials in IR #NMIBC ➡️Votes 5-to-4 against UGN-102 in IR NMIBC 👉cancernetwork.com/view/fda-odac-… ☑️Looks like future trials will need to be randomized and most importantly show stronger evidence regarding subsequent treatment burden

Excited to share our latest paper on ARPI monotherapy in #ProstateCancer Eur Urol Focus EAU YAU Prostate Cancer Working Group Marcin Miszczyk Alexander Giesen Juan Gómez Rivas Axel S. Merseburger steven joniau Giancarlo Marra Nyirády Dr. Péter Giorgio Gandaglia Shahrokh F. Shariat Pawel Rajwa Semmelweis University Urologic Oncology Research MedUni Vienna tinyurl.com/48d4hdtk

I feel truly honoured to lead this important first-in-human trial using the Virtuoso Robotic System for something that is very close to my heart - En bloc resection of bladder tumour. #UroSoMe (1/n) youtu.be/gTUv-cq-ICI?si…

#ASCO25 Zelenectide vs EV: a small peptide (Zele) with same payload & target as EV, but faster renal clearance. 💥A new twist in Nectin-4 targeting for UC. Matt Galsky Ignacio Duran Andrea Necchi

🧬 Our study on molecular profiling of 99 cases of micropapillary urothelial carcinoma (MPUC): • Most common mutations: TP53, TERT, ARID1A, ERBB2 • ERBB2 alterations in 24%: Amplifications, Missense mutations (most common: p.S310F) • Only ERBB2 amplifications associated with:

The management of #BladderCancer must begin with a pragmatic understanding of the molecular landscape. Lars Dyrskjøt kicks off scientific lectures at our 12th Scottish Bladder Cancer Symposium with an amazing talk. Ashish M. Kamat, MD, MBBS 💙alison birtle Fight Bladder Cancer

Update letter from Merck on TICE BCG timed for #ASCO25 “We are on track to complete the project on time and expect our plant to open by late 2026 ... facility is expected to triple our TICE BCG manufacturing capacity … meet the needs of physicians and patients for the